A Phase 2 interventional study of Rapcabtagene autoleucel and Active Comparator in ANCA Associated Vasculitis (AAV), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 39 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in United States — 8 open to participants now, 15 under way, 1 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States.
Among the 35 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in United States, this one is the 11th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, reaches primary completion later than 12 of the 14 other live ones, and was the 32nd registered.
158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.
Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →8 of the 35 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in United States are open now. Recruiting first, the newest first:
Fate Therapeutics · Sites in United States
Ages 18–70
Cartesian Therapeutics · Sites in United States
Ages 12+
Nkarta, Inc. · Sites in United States
Ages 18–75
Fate Therapeutics · Sites in United States, France, Sweden and 1 more country
Ages 12–70
Amgen · Sites in United States, Czechia, Denmark and 4 more countries
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 13 · Phase 3 7 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 36 across 117 interventional studies indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Median enrollment 54 across the 32 interventional studies, 1,600 across the 3 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06388941Novartis PharmaceuticalsIptacopan in Patients With ANCA Associated Vasculitis | 2026-12-30 |
| NCT06152172David PorterCARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | 2027-02 |
| NCT06308978Fate TherapeuticsA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 35 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
This is a Phase 2, randomized, assessor-blinded active controlled study. This study comprises two cohorts:
After end of study (EOS), participants who received rapcabtagene autoleucel infusion will enter a long-term follow-up (LTFU) period lasting up to 15 years after rapcabtagene autoleucel infusion. This LTFU will be described in a separate study protocol.
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single infusion of rapcabtagene autoleucel (YTB323) and concomitant glucocorticoids as per protocol
Biological: Rapcabtagene autoleucel · Drug: Glucocorticoids
Comparator and concomitant glucocorticoids as per protocol
Other: Active Comparator · Drug: Glucocorticoids
Single infusion of rapcabtagene autoleucel
Active comparator option as per protocol
Concomitant glucocorticoids as per protocol
Event-free survival (EFS)
Event-free survival (EFS) defined as the time from Randomization to the first occurrence of as per protocol defined events.
Time frame: From randomization until the occurrence of an EFS event, up to approx. 4 years after randomization
Percentage of patients achieving complete remission
Complete remission is defined by Birmingham Vasculitis Activity Score version 3 (BVASv3)
Time frame: Up to Week 13
Adjusted annual cumulative GC dose between Randomization and analysis cutoff date
The adjusted annual cumulative glucocorticoid dose refers to the total amount of glucocorticoids administered to a patient over the course of a year, adjusted for any changes in dosage, and measured up to the defined week of treatment as per protocol.
Time frame: From randomization until the occurrence of an EFS event, up to approx. 4 years after randomization
ANCA seronegativity and sustaining ANCA seronegativity until the analysis cutoff date
ANCA seronegativity means that the patient tests negative for ANCA antibodies.
Time frame: From randomization until the occurrence of an EFS event, up to approx. 4 years after randomization
Change from baseline in estimated glomerular filtration rate (eGFR) at Week 39
Change from baseline in estimated glomerular filtration rate (eGFR) at Week 39.
Time frame: Up to Week 39
Change from baseline in symptoms of GPA/ MPA using the AAV-PRO at Week 39
Change from baseline in symptoms of GPA/ MPA using the AAV-PRO at Week 39.
Time frame: Up to Week 39
Change from baseline in Patient- Reported Outcome Measurement Information System (PROMIS)- Fatigue 7a at Week 91.
Change from baseline in PROMIS- Fatigue 7a at Week 91.
Time frame: Up to Week 91
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rapcabtagene autoleucel
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis →